iShares US Pharmaceuticals

Latest iShares US Pharmaceuticals News and Updates

  • uploads///generic drug savings
    Company & Industry Overviews

    Will Generic Drugs Help Curb Healthcare Costs?

    Reducing medical costs would be a high priority in all economies, and generic drugs could provide a solution.

    By VanEck
  • uploads///Chart
    Earnings Report

    What to Expect from Johnson & Johnson’s 4Q15 Earnings

    Johnson & Johnson has returned nearly 1.2% year-to-date while Sanofi, Merck, and Novartis have returned ~0.5%, -4.4%, and -3.5%, respectively.

    By Mike Benson
  • uploads///patent cliff
    Company & Industry Overviews

    Drug Patent Expirations: $190 Billion Is Up for Grabs

    According to estimates by Evaluate Pharma, a whopping $120 billion in sales was lost to patent expirations between 2009 and 2014.

    By VanEck
  • uploads///dna _
    Company & Industry Overviews

    Merck’s Relebactam Met Primary Endpoints in Phase 3 Study

    Merck’s Relebactam is an investigational drug for the treatment of certain forms of imipenem-non-susceptible bacterial infections.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    Pfizer Reports 1Q18 Earnings and Revenue Growth

    Pfizer (PFE) released its 1Q18 earnings today, reporting another strong quarter for the Innovative health business.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Bristol-Myers Squibb: What Do Its Other Segments Offer?

    Bristol-Myers Squibb’s (BMY) neuroscience segment’s sales declined by 63.0% in 2015 from 2014, while its immunoscience segment’s sales improved ~14.1%.

    By Mike Benson
  • uploads///pill _
    Healthcare

    These Pharma Stocks Offer the Most Upside Potential

    In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

    By Kenneth Smith
  • uploads///aerial view of various medical pills pharmaceutical
    Company & Industry Overviews

    An Easier Way to Understand the Pharma Industry

    In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

    By Sybil Prowse
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Dividends and Earnings Quality

    Pfizer’s dividend yield is 3.15%. The company’s historical dividend yield was 3.53% in 2017, while the five-year average yield is 3.44%.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Did Pfizer Stock Fare in Q3 2018?

    Nineteen analysts currently track Pfizer stock. The consensus rating for Pfizer stands at 2.63, which represents a “hold.”

    By Mike Benson
  • uploads///Chart  EPS Growth Rate
    Company & Industry Overviews

    A Review of Pharma Stocks’ EPS Growth Rates

    In this article, we’ll compare the EPS growth rates of Eli Lilly (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Eli Lilly’s Business Segments Performed in Q2 2018

    Eli Lilly and Company reports its business revenue under two segments: the Human Pharmaceutical segment and Elanco, the Animal Health segment.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    LLY’s Cardiovascular Products: Cialis and Effient Q2 Sales Fall

    Cialis reported revenues of $538.7 million in Q2 2018, a YoY 14.0% decrease compared to revenues of $627.3 million in Q1 2017.

    By Mike Benson
  • uploads///medicine _
    Company & Industry Overviews

    Pfizer’s Valuation Post-4Q17 Earnings

    Pfizer (PFE) reported revenue of $13.7 billion in 4Q17, a 1% rise compared to $13.6 billion in 4Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Pfizer: Analysts’ Ratings and Recommendations for 4Q17

    Wall Street analysts expect Pfizer’s (PFE) top line to increase ~0.7% to ~$13.72 billion in 4Q17. The EPS is expected to increase to $0.56 for 4Q17.

    By Mike Benson
  • uploads///Chart  Val
    Company & Industry Overviews

    Merck’s & Co.’s Valuation in January 2018

    For 3Q17, Merck surpassed Wall Street analysts’ estimates for EPS but missed the revenue estimate. It reported EPS of $1.11 on revenues of $10.3 billion.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Mylan’s Rest of the World Segment Performed in 3Q17

    Mylan’s (MYL) Rest of the World segment includes revenues from third-party sales of generics products and specialty segment products reported from countries including New Zealand, India, Japan, and Australia as well as emerging markets including Asia, Brazil, Africa, and the Middle East.

    By Mike Benson
  • uploads///Chart  Keytruda
    Company & Industry Overviews

    Behind the Latest Developments for Merck’s Keytruda

    Keytruda (pembrolizumab) is a prescription medicine from Merck’s (MRK) immuno-oncology franchise used for the treatment of various tumors.

    By Mike Benson
  • uploads///Xyrem
    Company & Industry Overviews

    This Could Drive Jazz Pharmaceuticals’ Revenue Growth

    In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of ~$298 million, which represents ~6% growth YoY and ~10% growth QoQ.

    By Daniel Collins
  • uploads///SIP
    Company & Industry Overviews

    Pfizer’s Sterile Injection Pharmaceuticals in 2Q17 and 1H17

    In 1H17, Sulperazon reported revenues of ~$232 million for 15% growth on a YoY basis.

    By Daniel Collins
  • uploads///Chart  Rev EPS
    Company & Industry Overviews

    Eli Lilly’s Valuations after Its 2Q17 Earnings

    Eli Lilly (LLY) surpassed Wall Street estimates in 2Q17, reporting earnings per share of $1.11 on revenues of ~$5.8 billion. Analysts estimated that the company would report EPS of $1.05 on revenues of $5.6 billion.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Johnson & Johnson’s 2Q17 Performance, by Segment

    Segment-wise performance Johnson & Johnson (JNJ) reported 2.9% growth in operating revenue between 2Q16 and 2Q17. However, the company missed analysts’ 2Q17 estimate and reported revenue of $18.8 billion due to a 1% foreign exchange impact. Analysts had forecast revenue of $19 billion. Johnson & Johnson’s business is broken down into the pharmaceuticals segment, consumer […]

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    The Future of JAZZ’s Low-Sodium Investigational Drugs

    A 9-mg dose of JAZZ’s Xyrem, which contains 1,640 mg of sodium, has caused physicians to be reluctant to prescribe the drug to ~20% of their patients.

    By Margaret Patrick
  • uploads///Chart  EPS
    Company & Industry Overviews

    Pfizer’s 2Q17 Earnings: What You Need to Know

    Pfizer (PFE) reported a 2% decline in its top line for its 2Q17 earnings, which were released on August 1.

    By Mike Benson
  • uploads///Chart  EPS
    Earnings Report

    Inside Pfizer’s 2Q17 Earnings: Analyst Estimates

    Pfizer (PFE) is set to release its 2Q17 earnings on August 1, 2017. Analysts estimate earnings per share of $0.66 on revenues of ~$13.1 billion for 2Q17.

    By Mike Benson
  • uploads///Chart  Rev
    Earnings Report

    Bristol-Myers Squibb Reports Growth in 2Q17

    Bristol-Myers Squibb’s top line rose nearly 6% to ~$5.1 billion in 2Q17 due to operational growth of 7% in its revenue.

    By Mike Benson
  • uploads///Chart  Revenues
    Earnings Report

    Eli Lilly’s 2Q17 Earnings Rose 8% Year-over-Year

    Eli Lilly and Company (LLY) released its 2Q17 earnings on July 25, 2017, reporting an 8.0% rise in its top line to $5.8 billion for 2Q17 compared to 2Q16.

    By Mike Benson
  • uploads///Chart  EPS
    Earnings Report

    Bristol-Myers Squibb’s 2Q17 Earnings: Analysts’ Estimates

    Headquartered in New York City, Bristol-Myers Squibb (BMY) is a leading American pharmaceutical company.

    By Mike Benson
  • uploads///Internal Medicine
    Company & Industry Overviews

    How Pfizer’s Internal Medicines Is Positioned in 2017

    In 2016, Pfizer’s (PFE) Chantix reported revenues of ~$842 million, which represents a ~25% YoY (year-over-year) rise.

    By Daniel Collins
  • uploads///Animal Health Revenues
    Company & Industry Overviews

    How Merck’s Animal Health Business Is Expected to Perform in 2017

    In 2016, Merck’s (MRK) Animal Health segment reported revenues of ~$3.5 billion, which reflected ~4% growth year-over-year.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    What Analysts Predict for Eli Lilly’s 2Q17 Earnings

    For 2Q17, analysts estimate that Eli Lilly will post EPS of $1.05 and revenues of $5.6 billion.

    By Mike Benson
  • uploads///Chart  Pharmaceutical
    Earnings Report

    Johnson & Johnson: Pharmaceuticals in 2Q17

    Pharmaceutical segment Johnson & Johnson’s (JNJ) pharmaceutical segment comprises its immunology, infectious disease, neuroscience, oncology, cardiovascular and metabolic, and pulmonary hypertension franchises. Immunology franchise The major blockbuster drugs under the immunology franchise are Remicade, Stelara, and Simponi/Simponi Aria. The immunology franchise reported revenue of $3 billion in 2Q17, including an operational decrease of ~1.9% and a […]

    By Mike Benson
  • uploads///Chart  Cons
    Earnings Report

    Johnson & Johnson’s 2Q17 Estimates: Consumer Healthcare

    Johnson & Johnson’s (JNJ) Consumer Healthcare segment includes the baby care, oral care, skincare, over-the-counter products, women’s health, and wound care franchises.

    By Mike Benson
  • uploads///Chart  EPS
    Company & Industry Overviews

    What Allergan’s Valuation as of July 13 Tells Us

    For 2Q17, Wall Street analysts estimate AGN’s EPS (earnings per share) to come in at $3.93, which would be a 17.5% growth over 2Q16.

    By Mike Benson
  • uploads///Chart  ZTS
    Miscellaneous

    Performance of Zoetis Stock in 2Q17

    Zoetis (ZTS) stock has risen ~17.3% in 2Q17, while it has risen ~15.4% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///Chart  Humalog
    Company & Industry Overviews

    FDA Approves Eli Lilly’s Humalog Junior KwikPen

    Eli Lilly (LLY) announced that the US Food and Drug Administration (or FDA) approved the Humalog Junior KwikPen for finer dose adjustments in the treatment of patients with diabetes on June 13, 2017.

    By Mike Benson
  • uploads///Healthcare Sector Outperforming Overall Market Since
    Macroeconomic Analysis

    The Larger Aims of Obamacare: An Overview

    The idea behind Obamacare was that it would embody legislation not only providing but mandating healthcare coverage for nearly everyone in the US.

    By Mary Sadler
  • uploads///National Health Expenditure as of
    Macroeconomic Analysis

    The Hybrid US Healthcare System: An Overview

    The US healthcare system is unique in the developed world as it lacks a uniform system and, according to Emanuel, had been largely inefficient before Obamacare.

    By Mary Sadler
  • uploads///Chart
    Company & Industry Overviews

    Johnson & Johnson’s Business Segment Performance

    Johnson & Johnson’s Medical Devices segment contributed nearly 35% to the company’s total revenues.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Eliquis: Bristol-Myers Squibb’s Key Cardiovascular Drug

    Bristol-Myers Squibb’s (BMY) cardiovascular segment consists of its key drug, Eliquis. The segment contributed nearly 18.0% to the company’s total revenues in 4Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Mylan’s EpiPen Controversy: Is It a Brand or a Generic?

    Mylan has been embroiled in a controversy over whether its EpiPen is classified as a generic or a branded product and whether its 500.0% price hike is justified.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Bristol-Myers Squibb Saw Improved Eliquis Sales in 3Q16

    Bristol-Myers Squibb’s (BMY) cardiovascular segment consists of key drug Eliquis. This segment contributed nearly 18% of total revenues for 3Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at the Pfizer-Medivation Deal

    Pfizer-Medivation deal On September 27, 2016, Pfizer (PFE) completed the acquisition of Medivation (MDVN). The stock transaction is valued at $81.50 per Medivation share, resulting in a total enterprise value of ~$14 billion. What is Medivation? Medivation is a California-based biopharmaceutical company. It is focused on developing and commercializing innovative therapies for the treatment of […]

    By Mike Benson
  • uploads///Prevnar
    Company & Industry Overviews

    Why Pfizer’s Vaccines Business Is Declining

    With the acquisition of Baxter’s marketed vaccines, Pfizer (PFE) gained access to NeisVac-C and FSME-IMMUN/TicoVac.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    How Did Bristol-Myers Squibb’s Eliquis Perform?

    Bristol-Myers Squibb’s (BMY) cardiovascular segment consists of its key drug Eliquis. This segment contributed nearly 78% of total revenues for 2Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Recent Corporate and Pipeline Developments for Pfizer

    Pfizer acquired Bamboo Therapeutics, a biotechnology company focused on developing gene therapy for treating rare diseases.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Can We Expect from the Pfizer-Anacor Deal?

    Pfizer (PFE) announced the acquisition of Anacor Pharmaceuticals (ANAC) on May 16, 2016. The deal closed on June 23, 2016.

    By Mike Benson
  • uploads///ev to ebitda
    Company & Industry Overviews

    The Truth behind Horizon’s EV-to-EBITDA Performance

    On June 29, 2016, Horizon Pharma was trading at a forward EV-to-EBITDA multiple of 4.67x, which is at a discount when compared with peers.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    How Pfizer Continues Its Organic and Inorganic Growth

    Pfizer (PFE) completed the acquisition of Anacor Pharmaceuticals (ANAC) on June 23, 2016. The acquisition will strengthen Pfizer’s portfolio of inflammatory disease products.

    By Mike Benson
  • uploads/// App Economy
    Macroeconomic Analysis

    What’s behind the US Economy’s Remarkable Labor Market Strength?

    The US labor market has shown tremendous resilience amid concerns over various issues, like aging demographics.

    By Rick Rieder
  • uploads///global pharma market size
    Company & Industry Overviews

    How Is the Global Pharmaceutical Industry Doing?

    Some of the challenges the pharmaceutical industry faces include R&D failures, changes in regulatory procedures, litigation, patent expiries, and foreign currency movements.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    Opdivo: Bristol-Myers Squibb’s Blockbuster Drug

    Opdivo is a part of Bristol-Myers Squibb’s (BMY) alliance with Ono Pharmaceutical, and it reported revenues of $942 million in 2015.

    By Mike Benson
  • uploads///Actimmune
    Company & Industry Overviews

    Why Actimmune, Horizon’s Lead Orphan Product, Has Such Huge Potential

    After the Vidara merger in September 2014, Horizon Pharma gained access to Actimmune, which has been approved by the FDA for CGD and SMO.

    By Jillian Dabney
  • uploads/// innovative ability
    Macroeconomic Analysis

    How Has Technology Influenced Process and Product Innovation?

    One of the most prominent effects of technology is on the asset side of the balance sheet. Many technologies drive companies to employ fewer assets in order to generate higher returns.

    By Rick Rieder
  • uploads///Chart
    Company & Industry Overviews

    Bristol-Myers Squibb’s Cardiovascular Segment: What Is Eliquis?

    Bristol-Myers Squibb’s (BMY) cardiovascular segment’s key drug is Eliquis. This segment contributed nearly 11.2% of total revenues in 2015.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    JNJ’s Mature State Helps It to Consistently Pay Dividends

    On January 27, 2016, Johnson & Johnson (JNJ) was trading at a forward price-to-earnings multiple of ~15.6x.

    By Mike Benson
  • uploads///Chart  Pharma
    Earnings Report

    JNJ’s Blockbuster Drug Remicade Sees Flat Revenues in 4Q15

    JNJ’s pharmaceutical segment comprises its immunology, infectious disease, neuroscience, oncology, and cardiovascular and metabolics businesses.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    The RESONATE-2 Study for Johnson & Johnson’s Drug Imbruvica

    Imbruvica is a drug co-developed by Cilag GmbH International, a Johnson & Johnson subsidiary, and Pharmacyclics, a subsidiary of AbbVie (ABBV).

    By Mike Benson
  • uploads///Chart
    Miscellaneous

    CheckMate -066 Study Supports Opdivo’s Approval

    The FDA has now approved Opdivo for the treatment of BRAF WT (wild-type) melanoma, based on the results of a phase 3 study called CheckMate -066.

    By Mike Benson
  • uploads///Chart
    Miscellaneous

    CheckMate -025 Study Supports Opdivo’s Approval

    The FDA has now approved Opdivo for the treatment of advanced RCC (renal cell carcinoma) based on the results of a phase 3 study called CheckMate -025.

    By Mike Benson
  • uploads///Chart
    Miscellaneous

    FDA Approves Opdivo for Additional Indications

    Opdivo is one of Bristol-Myers Squibb’ recent oncology drugs, already approved by the FDA for the treatment of patients with melanoma and advanced NSCLC.

    By Mike Benson
  • uploads///Chart
    Miscellaneous

    Pfizer-Allergan Deal: Pfizer Will Combine with Allergan

    On November 23, two of the big pharmaceutical companies—Pfizer and Allergan—announced the biggest merger transaction ever in pharmaceuticals.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    JAVELIN Series: Clinical Studies of Avelumab

    The JAVELIN series is a clinical trial program for the use of Avelumab for treatment of multiple types of cancer, including Merkel cell carcinoma.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Avelumab Receives Breakthrough Therapy Designation

    Avelumab is under clinical investigation for metastatic Merkel cell carcinoma (or MCC), a type of skin cancer, and other cancers.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Existing Drugs for Renal Cell Carcinoma

    The FDA has accepted Bristol-Myers Squibb’s (BMY) supplemental biologics license application, or sBLA, for Opdivo for the treatment of patients with advanced renal cell carcinoma.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Opdivo’s sBLA Accepted by FDA for Priority Review

    Opdivo, one of Bristol-Myers Squibb’s most important products, is expected to be one of its major revenue contributors in the next five years.

    By Mike Benson
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.